In recent years, immune checkpoint inhibitor (ICI) therapy has emerged as a standard of care in the cancer treatment landscape beyond radiotherapy and chemotherapy.40,41 However, higher TIDE scores correlate with increased tumor immune evasion, leading to reduced response rates to ICI therapy.42,43 Therefore, we employed the TIDE score to predict ICI-related markers such as PD-L1/CD274. This evidence concerns the gene CD274 and cancer.